These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 281564)

  • 1. Correlation between tumor-specific systemic and in situ immunity as manifested by the delayed hypersensitivity response.
    Radov LA; Haskill JS; Korn JH; Fett JW
    J Natl Cancer Inst; 1979 Jan; 62(1):103-8. PubMed ID: 281564
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune response to inactivated syngeneic mammary adenocarcinoma cells. I. Role and regulation of antibody synthesis in DBA/2 mice.
    DeLustro F; Haskill JS
    J Natl Cancer Inst; 1980 Jan; 64(1):125-30. PubMed ID: 6928037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic adoptive transfer of immunity to 13762A rat mammary adenocarcinoma.
    Boyer CM; Kreider JW; Bartlett GL
    Cancer Res; 1981 Jun; 41(6):2394-400. PubMed ID: 6972251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune response to inactivated syngeneic mammary adenocarcinoma cells. II. Parameters of immunogenicity in DBA/2 mice.
    DeLustro F; Haskill JS
    J Natl Cancer Inst; 1980 Jan; 64(1):131-7. PubMed ID: 6928038
    [No Abstract]   [Full Text] [Related]  

  • 5. Tumor-specific antigen(s) in a spontaneous mammary carcinoma of C3H mice. II. Active immunization of mammary-tumor-agent-free mice.
    Suit HD; Silobrcic V
    J Natl Cancer Inst; 1967 Dec; 39(6):1121-8. PubMed ID: 6079865
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunologic factors influencing the intra-tumor localization of ADCC effector cells.
    Haskill S; Parthenais E
    J Immunol; 1978 Jun; 120(6):1813-7. PubMed ID: 659877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The present status of tumor immunology.
    Fisher B
    Adv Surg; 1971; 5():189-254. PubMed ID: 4941820
    [No Abstract]   [Full Text] [Related]  

  • 8. Suppression by cytosine arabinoside of serum-blocking factors of cell-mediated immunity to syngeneic transplants of mouse mammary tumors.
    Heppner GH; Calabresi P
    J Natl Cancer Inst; 1972 Apr; 48(4):1161-7. PubMed ID: 5023677
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunological resistance to pulmonary metastases in C3Hf-Bu mice bearing syngeneic fibrosarcoma of different sizes.
    Milas L; Hunter N; Mason K; Withers HR
    Cancer Res; 1974 Jan; 34(1):61-71. PubMed ID: 4809463
    [No Abstract]   [Full Text] [Related]  

  • 10. Experimental evaluation of in situ oncocide for primary tumor therapy: comparison of tumor-specific immunity after complete excision, cryonecrosis and ligation.
    Neel HB; Ketcham AS; Hammond WG
    Laryngoscope; 1973 Mar; 83(3):376-87. PubMed ID: 4690029
    [No Abstract]   [Full Text] [Related]  

  • 11. The development of cellular immunity to tumor cells.
    Cerilli J; Smith MC
    Surg Gynecol Obstet; 1972 May; 134(5):739-45. PubMed ID: 5064081
    [No Abstract]   [Full Text] [Related]  

  • 12. Protective serum effects in tumor immunity.
    Vaage J
    Isr J Med Sci; 1976; 12(4-5):334-43. PubMed ID: 939693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor specificity, serum inhibition, and influence of regional lymph nodes on cytotoxic macrophages from cultured bone marrow.
    Fisher B; Hanlon JT; Linta J; Saffer E
    Cancer Res; 1977 Oct; 37(10):3628-33. PubMed ID: 908011
    [No Abstract]   [Full Text] [Related]  

  • 14. Cellular cytotoxicity and serum inhibition in normal mice following transfer of xenogeneic tumor-sensitized cells.
    Fisher B; Wolmark N; Saffer EA
    Cancer Res; 1979 Dec; 39(12):4772-6. PubMed ID: 498106
    [No Abstract]   [Full Text] [Related]  

  • 15. A morphometrical analysis of lymph node responses to tumors of different immunogenicity.
    van de Velde CJ; Meyer CJ; Cornellsse CJ; van der Velde EA; van Putten LM; Swaveling A
    Cancer Res; 1978 Mar; 38(3):661-7. PubMed ID: 626970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum therapy for radiation-induced impairment of immune resistance to metastasis.
    Vaage J; Agarwal S
    Cancer Res; 1977 Oct; 37(10):3556-60. PubMed ID: 908007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of an immunoresistant and an immunosusceptible ascites subline from murine tumor TA3. I. Transplantability, morphology, and some physicochemical characteristics.
    Friberg S
    J Natl Cancer Inst; 1972 May; 48(5):1463-76. PubMed ID: 5030958
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunity to a TA3 tumor subline that grows in allogeneic hosts elicited by strain-specific TA3 tumor cells.
    Lippman MM; Venditti JM; Kline I; Elam DL
    Cancer Res; 1973 Apr; 33(4):679-84. PubMed ID: 4696468
    [No Abstract]   [Full Text] [Related]  

  • 19. Changes in lymphoreticular tissues during growth of a murine adenocarcinoma. 3. Plaque-forming cell response in lymph nodes and spleen.
    Rowland GF; Edwards AJ; Hurd CM; Sumner MR
    J Natl Cancer Inst; 1971 Aug; 47(2):321-7. PubMed ID: 4934422
    [No Abstract]   [Full Text] [Related]  

  • 20. Humoral and cellular immune factors in the systemic control of artifically induced metastases in C3Hf mice.
    Vaage J
    Cancer Res; 1973 Aug; 33(8):1957-65. PubMed ID: 4720805
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.